The REGN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the REGN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The REGN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View REGN Detailed Price Forecast - CNN Money||View REGN Detailed Summary - Google Finance|
|View REGN Detailed Summary - Yahoo! Finance||View REGN Stock Research & Analysis - Zacks.com|
|View REGN Trends & Analysis - Trade-Ideas||View REGN Major Holders - Barrons|
|View REGN Call Transcripts - NASDAQ||View REGN Breaking News & Analysis - Seeking Alpha|
|View REGN Annual Report - CompanySpotlight.com||View REGN OTC Short Report - OTCShortReport.com|
|View REGN Fundamentals - TradeKing||View REGN SEC Filings - Bar Chart|
|View Historical Prices for REGN - The WSJ||View Performance/Total Return for REGN - Morningstar|
|View the Analyst Estimates for REGN - MarketWatch||View the Earnings History for REGN - CNBC|
|View the REGN Earnings - StockMarketWatch||View REGN Buy or Sell Recommendations - MacroAxis|
|View the REGN Bullish Patterns - American Bulls||View REGN Short Pain Metrics - ShortPainBot.com|
|View REGN Stock Mentions - StockTwits||View REGN Stock Mentions - PennyStockTweets|
|View REGN Stock Mentions - Twitter||View REGN Investment Forum News - Investor Hub|
|View REGN Stock Mentions - Yahoo! Message Board||View REGN Stock Mentions - Seeking Alpha|
|View Insider Transactions for REGN - SECform4.com||View Insider Transactions for REGN - Insider Cow|
|View REGN Major Holdings Summary - CNBC||View Insider Disclosure for REGN - OTC Markets|
|View Insider Transactions for REGN - Yahoo! Finance||View Institutional Holdings for REGN - NASDAQ|
|View REGN Stock Insight & Charts - FinViz.com||View REGN Investment Charts - StockCharts.com|
|View REGN Stock Overview & Charts - BarChart||View REGN User Generated Charts - Trading View|
Analysts’ Recommendations for Exelixis in April 2018
Posted on Thursday April 19, 2018
In February 2018, Exelixis (EXEL) and its partner Daiichi Sankyo announced that it had submitted a regulatory application for esaxerenone therapy to the Japanese Pharmaceutical and Medical Devices Agency for the treatment of individuals with hypertension. According to the prior agreement between Exelixis and Daiichi Sankyo, Exelixis is set to receive a milestone payment of $20 million from Daiichi Sankyo. Daiichi Sankyo’s regulatory application has been supported by the results of Phase 3 trials evaluating the safety and efficacy of esaxerenone in individuals with essential hypertension compared to eplerenone.
AbbVie Inc. Is a Clear Value Play in Biotech Stocks
Posted on Tuesday April 17, 2018
Since topping over $120 a share three distinct times since February, shares of AbbVie Inc. (NYSE:ABBV) are still down around 25 percent. Whether the stock was perfectly priced or investors wanted an excuse to lock in profits, ABBV stock still has tremendous value and growth ahead. On March 22, AbbVie reported disappointing Phase 2 data for its Rova-T study that sent its shares lower.
Upadacitinib Could Drive AbbVie’s Long-Term Growth
Posted on Monday April 16, 2018
In April 2018, AbbVie (ABBV) positive results for its Phase 3 SELECT-COMPARE trial, which evaluated the safety and efficacy of upadacitinib for adults with moderate-to-severe rheumatoid arthritis. The trial met its primary endpoint of improved ACR201 scores and clinical remission.
Exploring the Growth of Regeneron’s Praluent
Posted on Thursday April 12, 2018
Regeneron Pharmaceuticals’ (REGN) Praluent is marketed in the United States as an adjunct to diet and maximally tolerated statin therapy for treating adults with heterozygous familial hypercholesterolemia (or HeFH) or clinical atherosclerotic cardiovascular disease (or ASCVD). Praluent is also marketed in Japan and some countries in the European Union. Praluent is a fully human monoclonal antibody inhibitor of PCSK9.